IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1624

Examiner: B. Coleman

INFORMATION DISCLOSURE STATEMENT

PHARMACEUTICAL COMPOSITIONS CONTAINING NEW POLYMORPHIC

FORMS OF OLANZAPINE AND **USES THEREOF**

33396-177202

December 27, 2001

Assistant Commissioner for Patents Washington, D.C. 20231

In re Patent Application of

Y. HAMIED et al

December 27, 2001

Unknown

Inventors:

Appln. No.:

Atty. Dkt.:

Filed:

For:

Sir:

In accordance with the duty of disclosure, the applicants inform the Examiner of the documents cited during prosecution of the parent application, 09/540,749. Applicants also notify the Examiner of newly cited references which are listed on the attached copy of the PTO-1449. Applicants respectfully request the Examiner to initial and return a copy of the PTO-1449's as indication that the references have been considered.

Applicant's note that the copy of newly cited reference AM, submitted herewith, is missing two pages. Applicant will obtain and submit a full copy of this reference.



If a fee is required, please charge Deposit Account Number 22-0261 accordingly and notify the undersigned.

Respectfully submitted,

Keith G. Haddaway

Registration No. 46,180

VENABLE

Post Office Box 34385

Washington, D.C. 20043-9998

KGH/sat/::ODMA\PCDOCS\DC2DOCS1\340942\1